See more : PION Group AB (publ) (PION-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of AREV Life Sciences Global Corp. (AREVF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AREV Life Sciences Global Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Union Electric Company (UEPEO) Income Statement Analysis – Financial Results
- Wuhan Tianyu Information Industry Co., Ltd. (300205.SZ) Income Statement Analysis – Financial Results
- Shi Shi Services Limited (8181.HK) Income Statement Analysis – Financial Results
- Element Nutritional Sciences Inc. (ELNSF) Income Statement Analysis – Financial Results
- Dishman Carbogen Amcis Limited (DCAL.NS) Income Statement Analysis – Financial Results
AREV Life Sciences Global Corp. (AREVF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.arevlifesciences.com
About AREV Life Sciences Global Corp.
AREV Life Sciences Global Corp., an integrated life science discovery company, produces and sells functional ingredients in Canada. The company's CBD-infused products, include Canna-Mulsion and NaturVax, anti- viral supplements; NaturRelax, a natural Sleep Aid; Natur Relief, an anti-inflator and pain relief product; and white label cannabis products, as well as a range of THC products, and cannabis skincare products and medicinal oils and edibles. Its ingredients are used in products that are targeted for sale in the natural health, medical, functional food, nutraceutical, sports nutrition, and bioceutical markets. In addition, the company's products address the areas of health, which include sleep deprivation, insomnia, anxiety, pain, and inflammatory conditions, as well as other specific ailments. Further, it offers nutraceutical product formulations under the Bare brand name; and ready-to-use therapeutic food products under the SUS-TAINN name. The company was formerly known as AREV NanoTec Brands Inc. and changed its name to AREV Life Sciences Global Corp. in August 2021. AREV Life Sciences Global Corp. was incorporated in 2005 and is based in Coquitlam, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 49.11K | 255.00K | 190.58K | 194.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103.55K | 39.50K | 0.00 | 300.00K |
| Cost of Revenue | 19.97K | 146.45K | 148.65K | 65.56K | 52.47K | 51.58K | 7.20K | 356.00 | 44.75K | 0.00 | 0.00 | 13.12K | 11.92K | 0.00 | 112.94K |
| Gross Profit | 29.14K | 108.54K | 41.92K | 129.13K | -52.47K | -51.58K | -7.20K | -356.00 | -44.75K | 0.00 | 0.00 | 90.43K | 27.59K | 0.00 | 187.06K |
| Gross Profit Ratio | 59.33% | 42.57% | 22.00% | 66.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 87.33% | 69.84% | 0.00% | 62.35% |
| Research & Development | 84.02K | 148.33K | 128.01K | 1.15M | 195.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.99K | 133.78K |
| General & Administrative | 986.01K | 1.44M | 561.76K | 1.96M | 1.53M | 733.00K | 207.98K | 81.02K | 29.60K | 33.17K | 40.98K | 24.68K | 57.14K | 198.97K | 272.60K |
| Selling & Marketing | 205.91K | 186.21K | 5.29K | 42.98K | 108.88K | 39.79K | 10.77K | 2.03K | 0.00 | 402.00 | 7.56K | 3.53K | 252.00 | 786.00 | 9.66K |
| SG&A | 1.19M | 1.63M | 567.06K | 2.01M | 1.64M | 772.79K | 218.75K | 81.02K | 29.60K | 33.57K | 48.54K | 28.22K | 57.39K | 199.76K | 282.26K |
| Other Expenses | -1.23M | -4.63K | 0.00 | -97.38K | -41.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 49.11K | 1.92M | 843.72K | 3.22M | 1.69M | 824.38K | 225.95K | 81.38K | 29.85K | 33.82K | 48.79K | 28.47K | 71.93K | 238.67K | 417.18K |
| Cost & Expenses | 1.49M | 1.92M | 843.72K | 3.22M | 1.69M | 824.38K | 225.95K | 81.38K | 29.85K | 33.82K | 48.79K | 41.59K | 83.85K | 238.67K | 530.12K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.25K | 6.95K |
| Interest Expense | 6.09K | 46.23K | 58.82K | 73.22K | 40.17K | 36.63K | 25.71K | 2.20K | 305.00 | 193.00 | 159.00 | 246.00 | 916.00 | 0.00 | 911.00 |
| Depreciation & Amortization | 125.59K | 146.45K | 148.65K | 65.56K | 52.47K | 51.58K | 7.20K | 356.00 | 255.00 | 255.00 | 255.00 | 255.00 | 255.00 | 915.00 | 1.14K |
| EBITDA | -1.31M | -797.63K | -504.49K | -3.05M | -1.64M | -797.45K | -218.75K | -81.60K | -29.60K | -33.57K | -48.54K | 62.21K | -44.09K | -249.50K | -228.98K |
| EBITDA Ratio | -2,672.26% | -596.16% | -264.72% | -1,520.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 60.08% | -111.62% | 0.00% | -76.33% |
| Operating Income | -1.39M | -1.67M | -653.14K | -3.03M | -1.69M | -849.03K | -225.95K | -81.96K | -29.85K | -33.82K | -48.79K | 61.96K | -44.35K | -250.41K | -230.12K |
| Operating Income Ratio | -2,827.74% | -653.59% | -342.72% | -1,554.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 59.84% | -112.27% | 0.00% | -76.71% |
| Total Other Income/Expenses | -55.32K | 652.97K | -395.74K | -166.66K | -6.74M | -224.58K | -25.71K | -2.20K | -13.02K | -193.00 | -159.00 | -246.00 | 27.83K | 24.46K | 6.04K |
| Income Before Tax | -1.44M | -990.31K | -1.05M | -3.19M | -8.43M | -1.02M | -251.66K | -84.16K | -75.22K | -34.02K | -48.95K | 61.71K | -16.51K | -225.95K | -224.08K |
| Income Before Tax Ratio | -2,940.37% | -388.36% | -550.37% | -1,639.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 59.60% | -41.80% | 0.00% | -74.69% |
| Income Tax Expense | 0.00 | 46.23K | 58.82K | 73.22K | 40.17K | 11.97K | 0.00 | 0.00 | 305.00 | 0.00 | 0.00 | 0.00 | 916.00 | -12.72K | 0.00 |
| Net Income | -1.44M | -990.31K | -1.05M | -3.19M | -8.43M | -1.02M | -251.66K | -84.16K | -75.22K | -34.02K | -48.95K | 61.71K | -16.51K | -225.95K | -224.08K |
| Net Income Ratio | -2,940.37% | -388.36% | -550.37% | -1,639.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 59.60% | -41.80% | 0.00% | -74.69% |
| EPS | -0.05 | -0.05 | -0.07 | -0.36 | -1.47 | -0.42 | -24.40 | -16.45 | -13.07 | -6.23 | -7.57 | 9.75 | -2.80 | -38.28 | -37.97 |
| EPS Diluted | -0.05 | -0.05 | -0.07 | -0.36 | -1.47 | -0.42 | -24.40 | -16.45 | -13.07 | -6.23 | -7.57 | 9.75 | -2.80 | -38.28 | -37.97 |
| Weighted Avg Shares Out | 30.07M | 19.59M | 15.36M | 8.96M | 5.73M | 2.42M | 10.31K | 5.12K | 5.76K | 5.46K | 6.47K | 6.33K | 5.90K | 5.90K | 5.90K |
| Weighted Avg Shares Out (Dil) | 30.07M | 19.59M | 15.36M | 8.96M | 5.73M | 2.42M | 10.31K | 5.12K | 5.76K | 5.46K | 6.47K | 6.33K | 5.90K | 5.90K | 5.90K |
AREV Nanotec Board of Directors Welcomes Kevin Phelps
Source: https://incomestatements.info
Category: Stock Reports